Scientific Letters
Vol. 18 No. 1 (2026): Mediterranean Journal of Hematology and Infectious Diseases
Evaluation of Hepatitis B and C Reactivation in Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Received: November 13, 2024
Accepted: November 15, 2025
Accepted: November 15, 2025
37
Views
23
Downloads
Authors
Background: There is little data regarding hepatitis B (HBV) and C (HCV) prevalence in chronic myeloid leukemia (CML) patients at diagnosis and hepatitis reactivation during tyrosine kinase inhibitors (TKI) treatment.
Downloads
Download data is not yet available.
Citations
Hehlmann R, Hochhaus A, Baccarani M. Chronic myeloid leukemia. The Lancet.2007;370(9584):342-350.
Masamoto Y, Kurokawa M. Targeting chronic myeloid leukemia stem cells: can transcriptional program be a druggable target for cancers?. Stem Cell Investigation. 2018; 5: 10. Published 2018 Apr 24.
Osman AEG, Deininger MW. Chronic Myeloid Leukemia: Modern therapies, current challenges and future directions. Blood Rev, 49 (2021), Article 100825. https://doi.org/10.1016/j.blre.2021.100825.
Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C et al (2002) Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 346(9):645–652.
Jabbour, E. (2016), Chronic myeloid leukemia: First-line drug of choice. Am. J. Hematol., 91: 59-66. https://doi.org/10.1002/ajh.24249.
Sacha T. Imatinib in chronic myeloid leukemia: an overview. Mediterranean Journal of Hematology and Infectious Diseases. 2014;6(1):e2014007. Published 2014 Jan 2.
Höglund, M., Sandin, F. & Simonsson, B. Epidemiology of chronic myeloid leukaemia: an update. Ann Hematol 94 (Suppl 2), 241–247 (2015). https://doi.org/10.1007/s00277-015-2314-2.
Delorda M, Foulonb S, Cayuelad JM, Rousselotf P, Bonastreb J. The rising prevalence of chronic myeloid leukemia in France. Leukemia Research June 2018; vol. 69.
Lai GM, Yan SL, Chang CS, Tsai CY. Hepatitis B reactivation in chronic myeloid leukemia patients receiving tyrosine kinase inhibitor. World J Gastroenterol 2013; 19(8): 1318-1321.
Inayat F, Song F, Ali NS, et al. Hepatitis B virus reactivation following imatinib therapy: A comparative review of 9 cases. Journal of Oncology Pharmacy Practice. 2019;25(6):1500-1508. doi:10.1177/1078155218790337.
de Lavallade H, Khoder A, Hart M, Sarvaria A, Sekine T, Alsuliman A, et al. Tyrosine kinase inhibitors impair B-cell immune responses in CML through off-target inhibition of kinases important for cell signaling. Blood. 2013 Jul;122(2):227–38.
Seiter K, Latremouille-Viau D, Guerin A, Ndife B, Habucky K, Tang DH, et al. Burden of infections among chronic myeloid leukemia patients receiving dasatinib or nilotinib: a real-world retrospective healthcare claims study in the United States. Adv Ther. 2018 Oct;35(10):1671–85.
EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. Journal of Hepatology 2017; vol. 67 j 370–398.
PA Harris, R Taylor, R Thielke, J Payne, N Gonzalez, JG. Conde, Research electronic data capture (REDCap) – A metadata-driven methodology and workflow process for providing translational research informatics support, J Biomed Inform. 2009 Apr;42(2):377-81.
PA Harris, R Taylor, BL Minor, V Elliott, M Fernandez, L O’Neal, L McLeod, G Delacqua, F Delacqua, J Kirby, SN Duda, REDCap Consortium, The REDCap consortium: Building an international community of software partners, J Biomed Inform. 2019 May 9 [doi: 10.1016/j.jbi.2019.103208].
Ministério da Saúde. Boletim Epidemiológico de Hepatites Virais 2023. Brasília: Secretaria de Vigilância em Saúde: Ministério da Saúde, jul. 2023.
Pattullo V. Hepatitis B reactivation in the setting of chemotherapy and immunosuppression - prevention is better than cure. World J Hepatol. 2015;7(7):954-967.
Ikeda K, Shiga Y, Takahashi A, Kai T, Kimura H, Takeyama K, Noji H, Ogawa K, Nakamura A, Ohira H, Sato Y, Maruyama Y. Fatal hepatitis B virus reactivation in a chronic myeloid leukemia patient during imatinib mesylate treatment. Leuk Lymphoma. 2006 Jan;47(1):155-7. doi: 10.1080/14639230500236818. PMID: 16321842.
Aldapt MB, Al-Mashdali AF, Obeidat K, Chandra P, Yassin M. Viral infections and incidence of reactivations in chronic myeloid leukemia patients. Oncology. 2023 Oct 17. doi: 10.1159/000534266. PMID: 37848004.
Niitsu N, Hagiwara Y, Tanae K, Kohri M, Takahashi N (2010) Prospective analysis of hepatitis B virus reactivation in patients with diffuse large B-cell lymphoma after rituximab combination chemotherapy. J Clin Oncol 28(34):5097–5100.
Pei, SN., Ma, MC., Wang, MC. et al. Analysis of hepatitis B surface antibody titers in B cell lymphoma patients after rituximab therapy. Ann Hematol 91, 1007–1012 (2012).
Steegmann JL, Baccarani M, Breccia M, Casado LF, García-Gutiérrez V, Hochhaus A, Kim DW, Kim TD, Khoury HJ, Le Coutre P, Mayer J, Milojkovic D, Porkka K, Rea D, Rosti G, Saussele S, Hehlmann R, Clark RE. European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. Leukemia. 2016 Aug;30(8):1648-71.
WANG, Ya-dan; CUI, Guo-hui; LI, Mian; GOWREA, Bhuveshwarnath; XIA, Jia; HU, Yu Hepatitis B virus reactivation in a chronic myeloid leukemia patient treated with imatinib mesylate, Chinese Medical Journal: July 2012 - Volume 125 - Issue 14 - p 2636-2637.
Yazici O, Şendur MAN, Aksoy S. Hepatitis C virus reactivation in cancer patients in the era of targeted therapies. World J Gastroenterol 2014; 20(22): 6716-6724.
Hanus JS, Ceretta LB, Simões PW, Tuon L. Incidence of hepatitis C in Brazil. Rev Soc Bras Med Trop [Internet]. 2015Nov;48(6):665–73.
Perrillo RP, Gish R, Falck-Ytter YT. American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology. 2015;148:221–244.e3.
Supporting Agencies
State of São Paulo Research Foundation (FAPESP), Institutional Scientific Initiation Scholarship Program (PIBIC) - National Council for Scientific and Technological Development (CNPq)How to Cite
“Evaluation of Hepatitis B and C Reactivation in Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors” (2026) Mediterranean Journal of Hematology and Infectious Diseases, 18(1), p. e2026001. doi:10.4084/MJHID.2026.001.
Copyright (c) 2026 Nathalia Sena de Oliveira Silva, Gislaine Duarte, Samuel de Souza Medina, Guilherme Brasil Duffles Amarante, Carmino Antonio de Souza, Katia Borgia Barbosa Pagnano
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
